Wells Fargo & Company MN lifted its position in shares of Athersys, Inc. (NASDAQ:ATHX) by 35.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 167,176 shares of the biopharmaceutical company’s stock after acquiring an additional 43,600 shares during the period. Wells Fargo & Company MN’s holdings in Athersys were worth $345,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ATHX. Thompson Davis & CO. Inc. boosted its position in shares of Athersys by 743.9% during the third quarter. Thompson Davis & CO. Inc. now owns 64,303 shares of the biopharmaceutical company’s stock valued at $132,000 after purchasing an additional 56,683 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Athersys by 345.5% during the second quarter. The Manufacturers Life Insurance Company now owns 88,561 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 68,680 shares during the last quarter. Rhumbline Advisers raised its stake in Athersys by 34.2% during the second quarter. Rhumbline Advisers now owns 110,064 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 28,030 shares during the last quarter. NEXT Financial Group Inc raised its stake in Athersys by 31.6% during the third quarter. NEXT Financial Group Inc now owns 128,950 shares of the biopharmaceutical company’s stock valued at $280,000 after buying an additional 31,000 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Athersys by 7.3% during the second quarter. Bank of New York Mellon Corp now owns 284,540 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 19,375 shares during the last quarter. Institutional investors own 21.10% of the company’s stock.

In other Athersys news, COO William Lehmann, Jr. sold 14,000 shares of Athersys stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $1.80, for a total transaction of $25,200.00. Following the completion of the transaction, the chief operating officer now owns 503,712 shares in the company, valued at $906,681.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold 29,000 shares of company stock valued at $51,075 in the last quarter. 9.40% of the stock is owned by company insiders.

Athersys, Inc. (NASDAQ:ATHX) opened at $1.73 on Monday. Athersys, Inc. has a one year low of $1.08 and a one year high of $2.63.

Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.06). The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.67 million. Athersys had a negative return on equity of 113.63% and a negative net margin of 746.04%. analysts expect that Athersys, Inc. will post -0.25 EPS for the current year.

A number of brokerages have issued reports on ATHX. Zacks Investment Research cut Athersys from a “buy” rating to a “hold” rating in a research note on Tuesday, October 10th. Maxim Group set a $12.00 price objective on Athersys and gave the company a “buy” rating in a research note on Thursday, November 16th. Finally, ValuEngine upgraded Athersys from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $7.17.

TRADEMARK VIOLATION WARNING: This story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/wells-fargo-company-mn-grows-position-in-athersys-inc-athx/1845616.html.

Athersys Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Want to see what other hedge funds are holding ATHX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Athersys, Inc. (NASDAQ:ATHX).

Institutional Ownership by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.